KRAS G12C

Assets acting on this target.

Class
KRAS G12C covalent inhibitor
Pathway
Irreversibly binds mutant KRAS G12C cysteine residue, locking RAS in an inactive GDP-bound state, blocking downstream MAPK signaling

KRAS is a small enzyme, a GTPase, that functions as a molecular switch within cells, cycling between an inactive state bound to GDP and an active state bound to GTP. In this active state it triggers the MAPK signaling cascade, a chain of protein activations that drives cell growth and division. The G12C mutation, a substitution at position 12 that introduces a reactive cysteine amino acid, impairs the cell's normal mechanisms for switching KRAS off, so the protein accumulates in its active, signal-sending form and drives uncontrolled proliferation. KRAS G12C covalent inhibitors exploit this exact mutation: they form an irreversible chemical bond with the mutant cysteine, but only when the protein is transiently in its inactive, GDP-bound conformation, trapping it there and shutting down downstream signaling. Because this cysteine is unique to the mutant protein, these drugs can act on tumor cells while largely sparing normal cells carrying unmutated KRAS, addressing a target once considered biologically inaccessible to small molecules. This mechanism is relevant across solid tumors where the G12C mutation occurs, including certain lung and colorectal cancers, and represents a broader strategy of mutation-specific targeting within the RAS family of oncogenes.

By indication

Related mechanisms

KRAS G12C drugs compared

13 drugs, stage by indication
13 drugs acting on KRAS G12C: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AdagrasibKrazatiBristol-Myers Squibb, Zai Labsmall moleculeApprovedApproved in Non-Small Cell Lung Cancer
SotorasibAmgensmall moleculeApprovedApproved in Advanced Metastatic Colorectal Cancer; Approved in Colorectal Cancer; Approved in Metastatic Colorectal Cancer; Approved in Non-Small Cell Lung Cancer
CalderasibMerck & Co.small moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
DivarasibRochesmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
GarsorasibAnfangningInventisBio, Sino Biopharmaceuticalsmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
GlecirasibAllist Pharmaceuticals, Jacobio Pharmaceuticalssmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
JMKX001899HUYABIO International, LLC., Jemincaresmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
OlomorasibEli Lillysmall moleculePhase 3Phase 3 in Non-Small Cell Lung Cancer
FulzerasibDupertGenFleet Therapeutics, Innovent Biologicssmall moleculePhase 2Phase 2 in Non-Small Cell Lung Cancer
ElironrasibRevolution Medicinessmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
FMC-376Frontier Medicines Corporationsmall moleculePhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer
BBO-8520TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)small moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer
HBI-2438HUYABIO International, LLC.small moleculePhase 1Phase 1 in Non-Small Cell Lung Cancer

← all mechanisms